[ET Net News Agency, 30 September 2021] Luye Pharma Group Ltd. (02186) said the Class 1
new chemical drug LPM3770164 Extendedrelease Tablets (LY03015) developed by the group has
obtained the approval from the Centre for Drug Evaluation of the National Medical Products
Administration in the People's Republic of China to initiate clinical trials.
LY03015 is an innovative small molecule compound product indicated for the treatment of
tardive dyskinesia and Huntington's disease. (RC)